secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2024-09-24T23:59:59+00:00
Accession:  0001193125-24-224139
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin reaffirms long-term guidance: ~$4B revenue by 2027, 40% margin from 2026
--------------------------------------------------------------------------------

- Reaffirms ~$4B total revenues in 2027.
- Non-GAAP operating margin of 40% starting in 2026, growing to low- to mid-40% range.
- Targets >$1.25B operating cash flow per year starting in 2027.
- Mid-teen CAGR for total revenues through 2034.
- Potential treatments for skeletal conditions represent >$5B revenue opportunity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000119312524224139/0001193125-24-224139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000119312524224139/d887671d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-224139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer